{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:46:15Z","timestamp":1790765175310,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.jns.2004.11.023","type":"journal-article","created":{"date-parts":[[2004,12,28]],"date-time":"2004-12-28T23:59:44Z","timestamp":1104278384000},"page":"163-169","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Aspirin resistance in stroke: 2004"],"prefix":"10.1016","volume":"229-230","author":[{"given":"Laszlo K.","family":"Sztriha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Sas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Vecsei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2004.11.023_bib1","series-title":"Heart disease: a textbook of cardiovascular medicine","first-page":"995","article-title":"The vascular biology of atherosclerosis","author":"Libby","year":"2001"},{"key":"10.1016\/j.jns.2004.11.023_bib2","doi-asserted-by":"crossref","first-page":"39S","DOI":"10.1378\/chest.119.1_suppl.39S","article-title":"Platelet-active drugs: the relationships among dose, effectiveness, and side effects","volume":"119","author":"Patrono","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jns.2004.11.023_bib3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2004.11.023_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jns.2004.11.023_bib5","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/archinte.159.11.1248","article-title":"A metaregression analysis of the dose\u2013response effect of aspirin on stroke","volume":"159","author":"Johnson","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jns.2004.11.023_bib6","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0140-6736(99)05388-X","article-title":"Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) trial collaborators","volume":"353","author":"Taylor","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2004.11.023_bib7","first-page":"148S","article-title":"Coronary syndromes following aspirin withdrawal","volume":"vol. 124","author":"Ferrari","year":"2003"},{"key":"10.1016\/j.jns.2004.11.023_bib8","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0735-1097(02)03013-9","article-title":"Aspirin resistance: a new independent predictor of vascular events?","volume":"41","author":"Eikelboom","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jns.2004.11.023_bib9","doi-asserted-by":"crossref","first-page":"S170","DOI":"10.1016\/S0002-8703(98)70245-5","article-title":"Assessment of platelet function assays","volume":"135","author":"Nicholson","year":"1998","journal-title":"Am. Heart J."},{"key":"10.1016\/j.jns.2004.11.023_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-2007-995840","article-title":"PFA-100 system: a new method for assessment of platelet dysfunction","volume":"24","author":"Mammen","year":"1998","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.jns.2004.11.023_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jns.2004.11.023_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00062752-199909000-00012","article-title":"Laboratory markers of platelet activation and their clinical significance","volume":"6","author":"Michelson","year":"1999","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.jns.2004.11.023_bib13","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1055\/s-0038-1657677","article-title":"Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty","volume":"78","author":"Mueller","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jns.2004.11.023_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/14017439850140021","article-title":"The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction","volume":"32","author":"Hurlen","year":"1998","journal-title":"Scand. Cardiovasc. J."},{"key":"10.1016\/j.jns.2004.11.023_bib15","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0049-3848(93)90164-J","article-title":"Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients","volume":"71","author":"Grotemeyer","year":"1993","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jns.2004.11.023_bib16","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1161\/01.CIR.0000013777.21160.07","article-title":"Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events","volume":"105","author":"Eikelboom","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2004.11.023_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00415-003-0954-y","article-title":"Aspirin non-responder status in patients with recurrent cerebral ischemic attacks","volume":"250","author":"Grundmann","year":"2003","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2004.11.023_bib18","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jns.2004.11.023_bib19","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1161\/01.CIR.0000015422.86569.52","article-title":"Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?","volume":"105","author":"Halushka","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2004.11.023_bib20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0140-6736(98)05054-5","article-title":"Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation","volume":"353","author":"Undas","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2004.11.023_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1022066305399","article-title":"Aspirin resistance and genetic polymorphisms","volume":"14","author":"Cambria-Kiely","year":"2002","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.jns.2004.11.023_bib22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1046\/j.1365-2141.2000.02300.x","article-title":"Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa)","volume":"110","author":"Andrioli","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.jns.2004.11.023_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2004.11.023_bib24","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/S0140-6736(99)00498-5","article-title":"Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance","volume":"353","author":"Weber","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2004.11.023_bib25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/01.CIR.0000081770.51929.5A","article-title":"Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery","volume":"108","author":"Zimmermann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2004.11.023_bib26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.CIR.102.9.1007","article-title":"Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina","volume":"102","author":"Cipollone","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2004.11.023_bib27","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1161\/01.CIR.97.4.350","volume":"97","author":"Valles","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2004.11.023_bib28","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/01.CIR.89.5.1951","article-title":"Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin","volume":"89","author":"Larsson","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2004.11.023_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0049-3848(02)00210-4","article-title":"Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate","volume":"107","author":"Macchi","year":"2002","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jns.2004.11.023_bib30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0002-9149(02)02718-2","article-title":"Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin","volume":"90","author":"Sane","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jns.2004.11.023_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0049-3848(03)00008-2","article-title":"Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease","volume":"108","author":"Christiaens","year":"2002","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jns.2004.11.023_bib32","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1161\/01.CIR.92.9.2432","article-title":"Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin","volume":"92","author":"Hung","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2004.11.023_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.321.7252.13","article-title":"Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial","volume":"321","author":"Meade","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jns.2004.11.023_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.326.7380.82","article-title":"Research pointers: platelet responsiveness to aspirin in patients with hyperlipidaemia","volume":"326","author":"Friend","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jns.2004.11.023_bib35","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.2337\/diacare.26.12.3264","article-title":"Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial","volume":"26","author":"Sacco","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jns.2004.11.023_bib36","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/sj.ijo.0802312","article-title":"Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects","volume":"27","author":"Tamminen","year":"2003","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.jns.2004.11.023_bib37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1161\/01.STR.25.2.275","article-title":"Failure of aspirin treatment after stroke","volume":"25","author":"Bornstein","year":"1994","journal-title":"Stroke"},{"key":"10.1016\/j.jns.2004.11.023_bib38","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0140-6736(03)12560-3","article-title":"Parsing an enigma: the pharmacodynamics of aspirin resistance","volume":"361","author":"FitzGerald","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2004.11.023_bib39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","article-title":"Effect of ibuprofen on cardioprotective effect of aspirin","volume":"361","author":"MacDonald","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2004.11.023_bib40","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.0000087593.07533.9B","article-title":"Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs","volume":"108","author":"Kurth","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2004.11.023_bib41","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/bmj.327.7427.1322","article-title":"Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study","volume":"327","author":"Curtis","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jns.2004.11.023_bib42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0002-9149(96)00696-0","article-title":"Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)","volume":"79","author":"Nguyen","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jns.2004.11.023_bib43","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0002-9343(00)00492-7","article-title":"Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease","volume":"109","author":"Peterson","year":"2000","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jns.2004.11.023_bib44","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0735-1097(00)00638-0","volume":"35","author":"Latini","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jns.2004.11.023_bib45","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMcp012672","article-title":"Clinical practice. Aspirin for primary prevention of coronary events","volume":"346","author":"Lauer","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2004.11.023_bib46","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1067\/mtc.2001.111416","article-title":"Aspirin resistance after coronary artery bypass grafting","volume":"121","author":"Zimmermann","year":"2001","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.jns.2004.11.023_bib47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.STR.0000106763.46123.F6","article-title":"Antiplatelet effect of aspirin in patients with cerebrovascular disease","volume":"35","author":"Alberts","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.jns.2004.11.023_bib48","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/01.STR.25.12.2331","article-title":"Development of aspirin resistance in persons with previous ischemic stroke","volume":"25","author":"Helgason","year":"1994","journal-title":"Stroke"},{"key":"10.1016\/j.jns.2004.11.023_bib49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.STR.24.3.345","article-title":"Aspirin response and failure in cerebral infarction","volume":"24","author":"Helgason","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.jns.2004.11.023_bib50","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2004.11.023_bib51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1055\/s-0037-1613462","article-title":"Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement","volume":"89","author":"Muller","year":"2003","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jns.2004.11.023_bib52","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/01.CIR.0000072771.11429.83","article-title":"Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity","volume":"107","author":"Gurbel","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jns.2004.11.023_bib53","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The clopidogrel in unstable angina to prevent recurrent events trial investigators","volume":"345","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2004.11.023_bib54","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0002-8703(03)00260-6","article-title":"Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment of Congestive Heart Failure (PLUTO-CHF) trial","volume":"146","author":"Serebruany","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.jns.2004.11.023_bib55","first-page":"s1","article-title":"European Stroke Prevention Study 2. Efficacy and safety data","volume":"151","year":"1997","journal-title":"J. Neurol. Sci."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X04004460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X04004460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T15:50:47Z","timestamp":1548863447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X04004460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":55,"alternative-id":["S0022510X04004460"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2004.11.023","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}